Alpha interferon in the treatment of multiple sclerosis. update and experience in Cuba
Summary. Objectives. We present an update of specific treatment for multiple sclerosis (MS), especially the form with a clinical course of exacerbation-remission (ER), in which we consider the benefits of beta interferons, copolymer 1 and intravenous immunoglobulin. We discuss the properties of alpha interferon and its modes of action which are very similar to those of beta interferon. The main clinical trials in which various subtypes of alpha interferons were used are summarized. Patients and methods. We establish the elements which justify interest in studying this substance and present the main trials carried out in Cuba. These consist in an initial trial in 9 patients, with encouraging results in the clinical course ER-MS and following this, the findings of a preliminary study of the first 17 patients of a randomized, double-blind National Clinical Trial, in which a placebo was used for control. Conclusions. In view of these results we recommend that the study being carried out in Cuba to confirm the efficacy of alpha interferon in the ER-MS form be continued
Pacientes y métodos Se establecen los elementos que justifican el interés por explorar esta sustancia y se presentan los principales estudios realizados en Cuba, consistentes en la experiencia inicial en nueve pacientes con resultados alentadores en la forma clínica evolutiva exacerbaciónremisión y los hallazgos de un estudio preliminar del resultado en los primeros 17 pacientes del ensayo clínico nacional, aleatorizado, doblemente ciego y controlado con placebo en ejecución.
Conclusiones De acuerdo con estos resultados se recomienda continuar el estudio que se está realizando en Cuba para comprobar la eficacia del interferón alfa en la forma exacerbaciónremisión de la esclerosis múltiple
